Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator

Alexander H. R. Varey; Isabel Li; Mary‐Ann El Sharouni; Julie M. Simon; Aikaterini Dedeilia; Sydney Ch’ng; Robyn P.M. Saw; Andrew J. Spillane; Kerwin F. Shannon; Thomas E. Pennington; Michael Rtshiladze; Jonathan R. Stretch; Omgo E. Nieweg; Alexander C.J. van Akkooi; Ryan J. Sullivan; Genevieve M. Boland; Jeffrey E. Gershenwald; P. J. van Diest; Richard A Scolyer; Georgina V. Long; John F. Thompson; Serigne Lo

doi:10.1200/jco.23.01020

Abstract

1 min read

The MIA models offer accurate and personalized estimates of both RFS and OS in patients with stage II melanoma even in the absence of pathological staging with SN biopsy. These models were robust on external validations and may be used in everyday practice both with (ideally) and without performing SN biopsy to identify high-risk patients for further management strategies. An online tool will be available at the MIA website (Risk Prediction Tools).

Related publications

Article2020

Quantifying the additional prognostic value of sentinel lymph node status over established clinicopathologic primary tumor features for predicting survival outcomes in melanoma patients.

Serigne Lo, Mary‐Ann El Sharouni, Karijn P.M. Suijkerbuijk, Tasnia Ahmed, Witkamp Arjen, Anne Ε. Cust, V. Sigurdsson, P. J. van Diest, Richard A Scolyer, Carla H. van Gils, John F. Thompson

Article2022

A tool to predict survival outcomes and guide adjuvant immunotherapy recommendations for patients with stage II melanoma.

Alexander H. R. Varey, Georgina V. Long, Richard A Scolyer, Jeffrey E. Gershenwald, Julie M. Simon, John F. Thompson, Serigne Lo

Article2023

Population-based validation of the melanoma institute australia (MIA) and the memorial sloan-kettering cancer center (MSKCC) predictive tool for sentinel node status in patients with melanoma.

Rasmus Mikiver, Roger Olofsson Bagge, Michael A. Marchetti, Alexander Christopher Jonathan Van Akkooi, Daniel G. Coit, Christian Ingvar, Karolin Isaksson, Richard A Scolyer, John F. Thompson, Alexander H. R. Varey, Johan Lyth, Edmund K. Bartlett

Article2024

Predicting sentinel node positivity in patients with primary cutaneous melanoma: an international multicentre study validating and refining the MIA risk calculator

Alexander H. R. Varey, Caroline A. Gjorup, Annette H. Chakera, L. Rosenkrantz Hölmich, Marc Moncrieff, Alastair D. MacKenzie Ross, Oliver Cassell, Jianhua Ma, Marie Brinch-Møller Weitemeyer, Roger Olofsson Bagge, Siri Klausen, Vinícius F. Calsavara, João Pedreira Duprat Neto, Eduardo Bertolli, Sydney Ch’ng, Robyn P.M. Saw, Kerwin F. Shannon, Andrew J. Spillane, Omgo E. Nieweg, Jonathan R. Stretch, G.J. Mann, Jenny L. C. Geh,

Article2015

Neoadjuvant BRAF (dabrafenib) and MEK (trametinib) inhibition for high-risk resectable stage III and IV melanoma.

Jennifer A. Wargo, Rodabe N. Amaria, Merrick I. Ross, Robyn P.M. Saw, Jeffrey E. Gershenwald, Patrick Hwu, Sapna P. Patel, Isabella Claudia Glitza, Adi Diab, Richard Kefford, Richard A Scolyer, Helen Rizos, John F. Thompson, Kerwin F. Shannon, Andrew J. Spillane, Matteo S. Carlino, Alex Guminski, Lauren Simpson, Michael A. Davies, Georgina V. Long